Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Blackwood JK, Williamson SC, Greaves LC, Wilson L, Rigas AC, Sandher R, Pickard RS, Robson CN, Turnbull DM, Taylor RW, Heer R. In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. Journal of Pathology 2011, 225(2), 181-188.
• Binda O, Boyce M, Rush JS, Palaniappan KK, Bertozzi CR, Gozani O. A chemical method for labeling lysine methyltransferase substrates. ChemBioChem 2011, 12(2), 330-334.
• Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF. A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research 2011, 17(4), 792-804.
• Ray C, Khurram M, Mownah O, Kanwar A, Stamp S, Brassil J, Rees D, Philipson K, Peaston R, White K, Wood K, Thomas A, Cunningham A, Carter N, Flecknell P, Talbot D. A novel perfusion fluid for DCD donor kidneys; better as a flush or a storage medium?. In: Transplant International: 15th Congress of the ESOT and 22nd Annual Conference of the BSHI. 2011, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
• Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer 2011, 104(4), 593-598.
• Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Annals of Oncology 2011, 22(9), 2137-2143.
• Galanakis I, Vasdev N, Soomro N. A review of current hemostatic agents and tissue sealants used in laparoscopic partial nephrectomy. Reviews in Urology 2011, 13(3), 131-138.
• Powell J, El Dean H, Carrie S, Wilson JA, Paleri V. Achieving consensus in follow-up practice for routine ENT procedures: a Delphi exercise. Clinical Otolaryngology 2011, 36(1), 45-50.
• Bailey S, Skinner R, Carey P, Moorman A, Banda K, Banda F, Eden OB, Israels T, Molyneux E. Acute lymphoblastic leukarmia (ALL) in Malawi, progress in the first Malawi ALL protocol. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
• Harrison CJ. Acute Lymphoblastic Leukemia. Clinics in Laboratory Medicine 2011, 31(4), 631-647.
• Buitenkamp T, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel MM, Pieters R, de Haas V, Silverman LB, Schmiegelow K, Liang DC, Horibe K, Arico M, Cazzaniga G, Basso G, Rabin KR, Schrappe M, Cario G, Mann G, Mondelaers V, Lammens T, Cave H, Stark B, Moorman AV, Vora AJ, Hunger S, Pui CH, Mullighan CG, Manabe A, Escherich G, Kowalczyk J, Whitlock JA, Zwaan CM. Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Gabriel AS, Hassold TJ, Thornhill AR, Affara NA, Handyside AH, Griffin DK. An algorithm for determining the origin of trisomy and the positions of chiasmata from SNP genotype data. Chromosome Research 2011, 19(2), 155-163.
• Kendrew J, Eberlein CA, Blakey DC, Wedge SR, Foltz I, Kang P, Barry ST. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2 dependent angiogenesis without affecting ligand binding. Molecular Cancer Therapeutics 2011, 10(5), 770-783.
• Williamson SC, Rigas AC, Robson CN, Heer R, Heer R. An update on the prostate cancer stem cell model-CD133+ve stem cell enriched human prostate cells express active androgen receptor. In: British Journal of Surgery: Annual Meeting of the Society of Academic and Research Surgery. 2011, Dublin, Ireland: John Wiley & Sons Ltd.
• Sinclair PB, Parker H, An Q, Rand V, Ensor H, Harrison CJ, Strefford JC. Analysis of a breakpoint cluster reveals insight into the mechanism of intrachromosomal amplification in a lymphoid malignancy. Human Molecular Genetics 2011, 20(13), 2591-2602.
• Weatherhead S, Farr P, Swan D, Jamieson D, Hallinan J, Lloyd J, Wipat A, Reynolds N. Apoptosis of keratinocytes is a key mechanism in UVB-induced clearance of psoriasis. In: 41st Annual Meeting of the European Society for Dermatological Research. 2011, Barcelona, Spain: Nature Publishing Group.
• Gabriel AS, Thornhill AR, Ottolini CS, Gordon A, Brown AP, Taylor J, Bennett K, Handyside A, Griffin DK. Array comparative genomic hybridisation on first polar bodies suggests that non-disjunction is not the predominant mechanism leading to aneuploidy in humans. Journal of Medical Genetics 2011, 48(7), 433-437.
• Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST. Assessing the Activity of Cediranib, a VEGFR-2/-3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family. Molecular Cancer Therapeutics 2011, 10(5), 861-873.
• Ciechomska M, Lennard TWJ, Kirby JA, Knight AM. B lymphocytes acquire and present intracellular antigens that have relocated to the surface of apoptotic target cells. European Journal of Immunology 2011, 41(7), 1850–1861.
• Payne K, Wright P, Grant JW, Huang Y, Hamoudi R, Bacon CM, Du MQ, Liu H. BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma. British Journal of Haematology 2011, 155(1), 84-92.
• Holland JP, Waugh L, Horgan A, Paleri V, Deehan DJ. Cadaveric Hands-on Training for Surgical Specialties: Is This Back to the Future for Surgical Skills Development?. Journal of Surgical Education 2011, 68(2), 110-116.
• Britton KM, Kirby JA, Lennard TWJ, Meeson AP. Cancer Stem Cells and Side Population Cells in Breast Cancer and Metastasis. Cancers 2011, 3(2), 2106-2130.
• Jackson M, Heer R, El-Sherif A, Perros P, Thorpe A. Carcinoid tumour in an ileocystoplasty: A reminder to consider native bowel disease in the reconstructed urinary tract. British Journal of Medical and Surgical Urology 2011, 4(1), 39-41.
• Noble M, Ladbury JE. Catalysis and regulation. Current Opinion in Structural Biology 2011, 21(6), 775-776.
• Illingworth NA, Boddy AV, Daly AK, Veal GJ. Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. British Journal of Pharmacology 2011, 162(4), 989-999.
• Pal D, Williamson SC, Robson CN, Rigas AC, Heer R. Characterising potential for pluripotency induction in human prostate tissue. In: British Journal of Surgery: Annual Meeting of the Society of Academic and Research Surgery. 2011, Dublin, Ireland: John Wiley & Sons Ltd.
• Proctor SJ, Wilkinson J, Culligan D, Galloway M, Lucraft HH, Jones G, Mcnally R, Wood KM, Mainou-Fowler T, Watson G, Goodlad JR. Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin Lymphoma patients over 60ys evaluated as part of the Shield (Hodgkin elderly) Study. In: Annals of Oncology: 11th International Conference on Malignant Lymphoma. 2011, Lugano, Switzerland: Oxford University Press.
• Williamson SC, Mitter R, Rigas AC, Robson CN, Heer R. Comparative meta-analysis of the human prostate stem cell transcriptome demonstrates that progenitor cells are the site of malignant transformation. In: British Journal of Surgery: Annual Meeting of the Society of Academic and Research Surgery. 2011, Dublin, Ireland: John Wiley & Sons Ltd.
• de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JAE. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leukemia Research 2011, 35(9), 1233-1240.
• Johnson N, Li YC, Walton ZE, Cheng KA, Li DA, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Medicine 2011, 17(7), 875-882.
• Pearce MS, Salotti JA, McHugh K, Metcalf W, Kim KP, Craft AW, Parker L, Ron E. CT scans in young people in Northern England: trends and patterns 1993-2002. Pediatric Radiology 2011, 41(7), 832-838.
• Vela-Chávez T, Adam P, Kremer M, Bink K, Bacon CM, Menon G, Ferry JA, Fend F, Jaffe ES, Quintanilla-Martínez L. Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus. Leukemia and Lymphoma 2011, 52(3), 458-466.
• Bedwell C, Rowe D, Moulton D, Jones G, Bown N, Bacon CM. Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. Haematologica 2011, 96(2), 343-346.
• Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC. Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. Journal of Clinical Oncology 2011, 29(11), 1400-1407.
• Blakey K, Feltobower R, Parslow R, James P, Pozo BG, Stiller C, Vincent T, Norman P, McKinney P, Murphy M, Craft A, McNally R. Demographic analysis of osteosarcoma and ewing sarcoma family of tumours in 0-49 year olds in Great Britain, 1980-2005: A small area approach. Journal of Epidemiology & Community Health 2011, 65(s1), A94.
• Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117(7), 2129-2136.
• Bigley V, Haniffa M, Doulatov S, Wang XN, Dickinson R, McGovern N, Spence L, Pagan S, Carey C, Dimmick I, Chua I, Wallis J, Lordan J, Morgan C, Kumararatne DS, Doffinger R, van der Burg M, van Dongen J, Cant A, Jackson G, Dick JE, Hambleton S, Collin M. Dendritic cell, monocyte, B and NK lymphoid deficiency: a novel but potentially fatal haematological disorder curable with haematopoietic stem cell transplantation. In: Bone Marrow Transplantation: 37th European Group for Bone and Marrow Transplantation. 2011, Paris, France: Nature Publishing Group.
• Thornton JK, Taylor KM, Ford D, Valentine RA. Differential Subcellular Localization of the Splice Variants of the Zinc Transporter ZnT5 Is Dictated by the Different C-Terminal Regions. PLoS One 2011, 6(8), e23878.
• Fordham SE, Matheson EC, Scott K, Irving JAE, Allan JM. DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs. Leukemia 2011, 25(6), 1046-1049.
• Clapham KM, Bardos J, Finlay R, Golding BT, Griffen EJ, Griffin RJ, Hardcastle IR, Menear KA, Ting A, Turner P, Young GL, Cano C. DNA-dependent protein kinase (DNA-PK) inhibitors: Structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain. Bioorganic & Medicinal Chemistry Letters 2011, 21(3), 966-970.
• Grinev VV, Posrednik DV, Heidenreich O. Effective and specific control of aml1/eto gene expression in acute myeloid leukemia cells by lentivector-based RNA-interference. Molecular Biology 2011, 45(2), 300-308.
• Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE, Natl Canc Res Inst. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncology 2011, 12(8), 743-752.
• Arden C, Petrie JL, Tudhope SJ, Al-Oanzi Z, Claydon AJ, Beynon RJ, Towle HC, Agius L. Elevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasis. Diabetes 2011, 60(12), 3110-3120.
• Vasdev N, Moir J, Dosani MT, Williams R, Soomro N, Talbot D, Rix D. Endourological Management of Urolithiasis in Donor Kidneys prior to Renal Transplant. ISRN Urology 2011, 2011, 242690.
• Sieniawski MK, Lennard AL. Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies. Current Hematologic Malignancy Reports 2011, 6(4), 231-240.
• Cooles FAH, Jackson GH, Menon G, Isaacs JD. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology 2011, 50(4), 810-812.
• Ramsay AK, McCracken SRC, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, Nuttall RK, Seywright M, Marquez R, Keller E, Leung HY. ERK5 signalling in prostate cancer promotes an invasive phenotype. British Journal of Cancer 2011, 104(4), 664-672.
• Norman NA, Hogarth L, Panlilio L, Shoaib M. Establishing concurrent choice procedures with intravenous nicotine and sucrose in rats. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2011, Harrogate: Sage Publications Ltd.
• Esfandiari A, Shoaib M, Hogarth L, Panlilio L. Establishing pavlovian to instrumental transfer (PIT) with intravenous nicotine and sucrose in rats. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2011, Harrogate: Sage Publications Ltd.
• Brown M, Pearce M, Salotti J, Craft A, Hale J. European Bone Tumour Outcome Study (EBTOS): Overview of health related quality of life (QOL) in study cohort. In: Journal of Epidemiology & Community Health: IEA World Congress of Epidemiology. 2011, Edinburgh: BMJ Group.
• Carroll MA, Launay GG, Reed CD, Hobson SJ. Evaluation of tetraethylammonium bicarbonate as a phase transfer agent in the formation of [F-18]fluoroarenes in a microreactor. In: Journal of Labelled Compounds and Radiopharmaceuticals: 19th International Symposium on Radiopharmaceutical Sciences. 2011, Amsterdam, Netherlands: John Wiley & Sons Ltd.
• Blair HJ, Tompson S, Liu YN, Campbell J, MacArthur K, Ponting CP, Ruiz-Perez VL, Goodship JA. Evc2 is a positive modulator of Hedgehog signalling that interacts with Evc at the cilia membrane and is also found in the nucleus. BMC Biology 2011, 9(1), 14.
• Creutzig U, Zimmermann M, Bourquin J-P, Dworzak MN, Kremens B, Lehrnbecher T, von Neuhoff C, Sander A, von Stackelberg A, Schmid I, Starý J, Steinbach D, Vormoor J, Reinhardt D. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2011, (advance online publication).
• Chatterjee S, Frew J, Wilsdon JB, McCallum H, Mott J, Stevenson P, Dobrowsky W, Maxwell RJ, Nutting CM, Kelly CG. Final Results of Vortigern Study: CT Versus Pet-CT Based Tomotherapy Voluming and Dose Escalation in Oropharyngeal Squamous Cell Carcinoma (ISRCTN 33175361, UKCRN ID: 08/h0907/127) [meeting abstract]. Clinical Oncology 2011, 23(3), S26-S26.
• Overbeck-Zubrzycka D, Ali S, Kirby J, Lennard T. FOXP3 transcription factor regulates metastatic spread of breast cancer via control of expression of CXCR4 chemokine receptor. In: British Journal of Surgery: International Surgical Congress of the Association of Surgeons of Great Britain and Ireland. 2011, Bournemouth, UK: John Wiley & Sons Ltd.
• Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, Robson CN, Spencer-Dene B, Gamble SC, Powell SM, Wait R, Waxman J, Walker MM, Bevan CL. FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth. Cancer Research 2011, 71(3), 914-924.
• Anderson K, Lutz C, van Delft FW, Bateman CM, Guo YP, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, Kearney L, Enver T, Greaves M. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469(7330), 356-361.
• Menghi F, Jacques TS, Barenco M, Schwalbe EC, Clifford SC, Hubank M, Ham J. Genome-Wide Analysis of Alternative Splicing in Medulloblastoma Identifies Splicing Patterns Characteristic of Normal Cerebellar Development. Cancer Research 2011, 71(6), 2045-2055.
• Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, Hayden JT, Dyer S, Pfister S, Korshunov A, Brundler MA, Lowe J, Coyle B, Grundy RG. Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro-Oncology 2011, 13(8), 866-879.
• Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, Jones L, Masic D, Minto L, Morrison H, Ryan S, Robinson H, Sinclair P, Moorman A, Strefford J, Harrison CJ. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2011, 117(25), 6848-6855.
• Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T, NCRI Clinical Translational Radiot. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. British Journal of Cancer 2011, 105(5), 628-639.
• Patman GL, Anstee Q, Reeves HL. Hepatocellular Carcinoma in NASH: Is there a biological Rationale?. In: 9th Meeting of Therapy in Liver Diseases. 2011, Barcelona, Spain.
• Lee JS, Kim Y, Bhin J, Shin HJ, Nam HJ, Lee SH, Yoon JB, Binda O, Gozani O, Hwang D, Baek SH. Hypoxia-induced methylation of a pontin chromatin remodeling factor. PNAS 2011, 108(33), 13510-13515.
• Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer 2011, 105(3), 372-381.
• Rajan P, Dalgliesh C, Carling PJ, Buist T, Zhang CL, Grellscheid SN, Armstrong K, Stockley J, Simillion C, Gaughan L, Kalna G, Zhang MQ, Robson CN, Leung HY, Elliott DJ. Identification of Novel Androgen-Regulated Pathways and mRNA Isoforms through Genome-Wide Exon-Specific Profiling of the LNCaP Transcriptome. PLoS One 2011, 6(12), e29088.
• Coulthard SA, Redfern CPF, Vikingsson S, Lindqvist-Appell M, Skoglund K, Jakobsen-Falk I, Hall AG, Taylor GA, Hogarth LA. Increased Sensitivity to Thiopurines in Methylthioadenosine Phosphorylase-Deleted Cancers. Molecular Cancer Therapeutics 2011, 10(3), 495-504.
• Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR, Stratford IJ. Inhibition of PARP-1 by Olaparib (AZD2281) Increasesthe Radiosensitivity of a Lung Tumor Xenograft. Molecular Cancer Therapeutics 2011, 10(10), 1949-1958.
• Davison Z, de Blacquiere GE, Westley BR, May FEB. Insulin-like Growth Factor-Dependent Proliferation and Survival of Triple-Negative Breast Cancer Cells: Implications for Therapy. NeoPlasia 2011, 13(6), 504-515.
• Fong CYK, Parker CA, Hussain A, Liu JZ, Essink M, Kuehnel HJ, Lancaster DL, Pridham G, Payne D, O'Horo C, Krishnan S, Hancock J, Goulden N, Moorman AV, Richards S, Vora AJ, Saha V, Masurekar AN. Intramuscular PEG-Asparaginase At 1000 U/m(2) Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Ng WF, Tudhope SJ, von Delwig A, Lilic D. Invariant natural killer T (iNKT) cell deficiency in chronic mucocutaneous candidiasis - A consequence or a cause?. Immunology Letters 2011, 135(1-2), 180-183.
• Hambleton S, Salem S, Bustamente J, Bigley V, Boisson-Dupuis S, Azevedo J, Fortin A, Haniffa M, Ceron-Gutierrez C, Bacon CM, Menon G, Trouillet C, McDonald D, Carey P, Ginhoux F, Alsina L, Zumwalt TJ, Kong X, Kumararatne D, Butler K, Hubeau M, Feinberg J, Al-Muhsen S, Cant A, Abel L, Chaussabel D, Doffinger R, Talesnik E, Grumach A, Duarte A, Abarca K, Moraes-Vasconcelos D, Burk D, Berghuis A, Geissmann F, Collin M, Casanova J-L, Gros P. IRF8 Mutations and Human Dendritic-Cell Immunodeficiency. New England Journal of Medicine 2011, 365(2), 127-138.
• Powell J, Cooles FAH, Carrie S, Paleri V. Is undergraduate medical education working for ENT surgery? A survey of UK medical school graduates. Journal of Laryngology and Otology 2011, 125(9), 896-905.
• Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J. Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-ActivityStudies Leading to Improved Potency. Journal of Medicinal Chemistry 2011, 54(5), 1233-1243.
• Weatherhead SC, Farr PM, Jamieson D, Hallinan JS, Lloyd JL, Wipat A, Reynolds NJ. Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation. Journal of Investigative Dermatology 2011, 131(9), 1916-1926.
• Harrison CJ. Key pathways as therapeutic targets. Blood 2011, 118(11), 2935-2936.
• Dominguez-Escrig JL, Vasdev N, O'Riordon A, Soomro N. Laparoscopic partial nephrectomy: Technical considerations and an update. Journal of Minimal Access Surgery 2011, 7(4), 205-221.
• Wilson CH, Sanni A, Rix DA, Soomro NA. Laparoscopic versus open nephrectomy for live kidney donors. Cochrane Database of Systematic Reviews 2011, (11), CD006124.
• Ray C, Khurram M, Mownah O, Kanwar A, Stamp S, Brassil J, Rees D, White K, Wood K, Philipson K, Peaston R, Thomas A, Cunningham A, Flecknell P, Carter N, Talbot D. Large animal renal allotransplantation; a porcine recovery model to assess delayed graft function. In: Transplant International: 15th Congress of the ESOT and 22nd Annual Conference of the BSHI. 2011, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
• Bomken S, Buechler L, Rehe K, Ponthan F, Blair H, Heidenreich O, Vormoor J. Lentiviral Transduction of Patient Derived Leukaemic Blasts Allowing In Vivo Bioluminescent Monitoring in An NSG Model of Leukaemia Stem Cell Maintenance. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Culpin R, Sieniawski M, Anderson J, Angus B, Proctor S, Menon G, McCabe K, Milne P, Crosier S, Mainou-Fowler T. Mature microRNAs of the miR-17-92 cluster predict for disease outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with CHOP-R immunochemotherapy. In: International Journal of Molecular Medicine. 2011, Spandidos Publications.
• Watson AF, Liu JF, Bennaceur K, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lu XH, McDonnell JM, Newell DR, Noble MEM, Revill CH, Riedinger C, Xu Q, Zhao Y, Lunec J, Hardcastle IR. MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones. Bioorganic & Medicinal Chemistry Letters 2011, 21(19), 5916-5919.
• Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD. Medulloblastoma Comprises Four Distinct Molecular Variants. Journal of Clinical Oncology 2011, 29(11), 1408-1414.
• Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica 2011, 121(3), 381-396.
• Irving L, Mainou-Fowler T, Parker A, Ibbotson RE, Oscier DG, Strathdee G. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia. Epigenetics 2011, 6(3), 300-306.
• Strathdee G. Methylation markers in the clinical management of leukemia patients – Wave of the future or damp squib?. Epigenomics 2011, 3(4), 391-394.
• Jeyapalan JN, Noor DAM, Lee SH, Tan CL, Appleby VA, Kilday JP, Palmer RD, Schwalbe EC, Clifford SC, Walker DA, Murray MJ, Coleman N, Nicholson JC, Scotting PJ. Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance. British Journal of Cancer 2011, 105(4), 575-585.
• Culpin R, Pearce K, Bailey J, Pointon J, Sunter N, Bailey J, Evans P, Allsup D, Allan J, Mainou-Fowler T. MicroRNAs in B-cell chronic lymphocytic leukaemia (B-CLL): mature microRNAs of the miR-17-92 cluster predict for treatment free survival (TFS) in patients with B-CLL. In: International Journal of Molecular Medicine. 2011, Spandidos Publications.
• Elliott SL, Crawford C, Mulligan E, Summerfield G, Newton P, Wallis J, Mainou-Fowler T, Evans P, Bedwell C, Durkacz BW, Willmore E. Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. British Journal of Haematology 2011, 152(1), 61-71.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA. MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Allen CG, Hills RK, Evans CM, Lamb K, Sellar R, Moorman AV, Sale M, Liu-Yin JA, Burnett AK, Linch DC, Gale RE. Mutations in a Large Cohort of Young Adult Patients with Core Binding Factor Acute Myeloid Leukemia: Impact on Outcome and the Selection of Patients for Alternative Treatment Including Transplantation in First Complete Remission. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Das D, Chattopadyhay D, Patanwala I, Islam T, Walia D, Rose J, Jaques B, Manas DM, Hudson M, Reeves HL. NAFLD and the changing face of hepatocellular cancerER (HCC). In: Journal of Hepatology: 46th Annual Meeting of the European Association for the Study of the Liver (EASL). 2011, Berlin, Germany: Elsevier BV.
• Graham JE, Aslam T, Chattopadyhay D, Das D, Patanwala I, Rose J, Jaques BC, Manas D, Hudson M, Reeves H. NAFLD related HCC is rising dramatically in the North of England. In: Hepatology: 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2011, San Francisco, California, USA: John Wiley & Sons, Inc.
• Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of alpha(1)-Acid Glycoprotein. Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
• Armstrong JL, Corazzari M, Martin S, Pagliarini V, Falasca L, Hill DS, Ellis N, Al Sabah S, Redfern CPF, Fimia GM, Piacentini M, Lovat PE. Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition. Clinical Cancer Research 2011, 17(8), 2216-2226.
• Paleri V, Thomas L, Basavaiah N, Drinnan M, Mehanna H, Jones T. Oncological outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma: A systematic review and meta-analysis of English language literature. Cancer 2011, 117(12), 2668-2676.
• Carr-Wilkinson J, Griffiths R, Elston R, Goranov B, Redfern CPF, Gamble LD, Lunec J, Tweddle DA. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Cell Cycle 2011, 10(21), 3778-3787.
• Davies C, Hogarth LA, Dietrich PA, Bachmann PS, Mackenzie KL, Hall AG, Lock RB. p53-independent Epigenetic Repression of the p21(WAF1) Gene in T-cell Acute Lymphoblastic Leukemia. Journal of Biological Chemistry 2011, 286(43), 37639-37650.
• Mukhopadhyay A, Curtin NJ, Plummer ER, Edmondson RJ. PARP Inhibitors And Epithelial Ovarian Cancer: An Approach To Targeted Chemotherapy And Personalized Medicine. BJOG 2011, 118(4), 429-432.
• Bate J, Chisholm J, Heath P, Breuer J, Skinner R, Manley S, Patel S, Wheatley K, Ramsay M, Kearns P, Hambleton S. PEPtalk: post-exposure prophylaxis against varicella in children with cancer. Archives of Disease in Childhood 2011, 96(9), 841-845.
• Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival. Pediatric Hematology & Oncology 2011, 28(2), 106-114.
• Veuger SJ, Durkacz BW. Persistence of unrepaired DNA double strand breaks caused by inhibition of ATM does not lead to radio-sensitisation in the absence of NF-kappa B activation. DNA Repair 2011, 10(2), 235-244.
• Jamieson D, Boddy AV. Pharmacogenetics of genes across the doxorubicin pathway. Expert Opinion on Drug Metabolism and Toxicology 2011, 7(10), 1201-1210.
• Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy. European Journal of Cancer 2011, 47(10), 1556-1563.
• Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
• Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. Investigational New Drugs 2011, 29(6), 1406-1413.
• Plummer R. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?. Breast Cancer Research and Treatment 2011, 13(4), 218.
• Plummer R. Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?. In: 9th Conference on Madrid Breast Cancer. 2011, Madrid, Spain: BioMed Central Ltd.
• Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochemical Journal 2011, 436(3), 671–679.
• Al-Balool HH, Weber D, Liu Y, Wade M, Guleria K, Nam PL, Clayton J, Rowe W, Coxhead J, Irving J, Elliott DJ, Hall AG, Santibanez-Koref M, Jackson MS. Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. Genome Research 2011, 21(11), 1788-1799.
• Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, Angibaud P, Perera T, Fazal L, Ross D, Jones CG, Madin A, Benning RK, Vickerstaffe E, O'Brien A, Frederickson M, Reader M, Hamlett C, Batey MA, Rich S, Carr M, Miller D, Feltell R, Thiru A, Bethell S, Devine LA, Graham BL, Pike A, Cosme J, Lewis EJ, Freyne E, Lyons J, Irving J, Murray C, Newell DR, Thompson NT. Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models. Molecular Cancer Therapeutics 2011, 10(9), 1542-1552.
• Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer 2011, 47(13), 2052-2059.
• Blakey K, Feltbower R, Parslow R, James P, Pozo BG, Stiller C, Vincent T, Norman P, McKinney P, Murphy M, Craft A, McNally R. Primary bone cancer in 0-49 year olds in Great Britain, 1980-2005 and flouride in drinking water: A case of inequalities?. Journal of Epidemiology & Community Health 2011, 65(s1), A93-A94.
• Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJL, Leszl A, Litvinko N, Lo Nigro L, Morimoto A, Perot C, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood 2011, 117(26), 7102-7111.
• Coenen E, Raimondi S, Harbott J, Zimmermann M, Alonzo T, Auvrignon A, Beverloo B, Chang M, Creutzig U, Dworzak M, Forestier E, Gibson B, Hasle H, Harrison C, Heerema N, Kaspers G, Leszl A, Litvinko N, Lo Nigro L, Morimoto A, Perot C, Reinhardt D, Rubnitz J, Smith F, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan M, van den Heuvel-Eibrink M. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11Q23/MLL-rearranged AML patients: Results of an international study. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
• Shamim Z, Ryder LP, Christensen IJ, Toubert A, Norden J, Collin M, Jackson G, Dickinson AM, Muller K. Prognostic Significance of Interleukin-7 Receptor-alpha Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A Confirmatory Study. Transplantation 2011, 91(7), 731-736.
• Nicholson L, Evans C, Matheson EC, Minto L, Keilty C, Schwab C, Harrison CJ, Hall AG, Redfern C, Whetton A, Irving J. Quantitative Proteomic Analysis Reveals Maturation As a Mechanism Underlying Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia and PAX5 As a Re-Sensitising Therapeutic Target. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. Rapid Diagnosis of Medulloblastoma Molecular Subgroups. Clinical Cancer Research 2011, 17(7), 1883-1894.
• Ryan SL, Rand V, Schwab C, Morrison H, Matheson E, Minto L, Rahman T, Keavney B, Bown N, Skinner R, Schnittger S, Santibanez-Koref M, Grossmann V, Kohlmann A, Irving J, Harrison CJ. Ras Signalling Pathway and Novel Target Genes Related to Down Syndrome Contribute to the Development of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in iAMP21 Patients. In: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Levesley J, Lusher ME, Lindsey JC, Clifford SC, Grundy R, Coyle B. RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro-Oncology 2011, 13(12), 1265-1276.
• Sturgess K, Slatter M, Bigley V, Haniffa M, Wang XN, Dickinson R, McGovern N, Jardine L, Pagan S, Chua I, Wallis J, Lordan J, Morgan C, Cant A, Gennery A, Edmondson R, Bacon C, Black F, Kirkham N, Jackson GH, Hambleton S, Collin MP. Reduced Intensity Hematopoietic Stem Cell Transplant Rescues Immune Function and Corrects Pulmonary Alveolar Proteinosis in DCML Deficiency/GATA 2 Mutation. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Gaughan L, Stockley J, Wang N, McCracken S, Truemann A, Armstrong K, Shaheen F, Watt K, McEwan I, Wang C, Pestell RG, Robson CN. Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Research 2011, 39(4), 1266-1279.
• Gibson BES, Webb DKH, Howman AJ, De Graaf SSN, Harrison CJ, Wheatley K, United Kingdom Childhood Leukaemia, Dutch Childhood Oncology Grp. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial. British Journal of Haematology 2011, 155(3), 366-376.
• Thathia S, Ferguson S, Bown N, Powell H, Strathdee G. RGS proteins are at the crossroads of the FLT3 and HOX pathways in leukaemia development. Oncogene 2011. Submitted.
• Basta NO, James PJ, Craft AW, McNally RJQ. Seasonality in the incidence of cervical carcinoma in teenagers and young adults in northern England, 1968-2005. Chronobiology International 2011, 28(9), 819-824.
• Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Benard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Canete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). British Journal of Cancer 2011, 105(12), 1940-1948.
• Rigas AC, Jaiswal N, Williamson SC, Pickard R, Robson CN, Heer R. Side population in human bladder cancer enriches for cancer stem cells that can be targeted by MAPK inhibition. In: British Journal of Surgery: Annual Meeting of the Society of Academic and Research Surgery. 2011, Dublin, Ireland: John Wiley & Sons Ltd.
• Ponthan F, McNeill H, Buechler L, Grinev V, Vormoor J, Heidenreich O. Significance of Fusion Genes for Maintenance of Leukaemia. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Gomaa MS, Bridgens CE, Aboraia AS, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates. Journal of Medicinal Chemistry 2011, 54(8), 2778-2791.
• Pearce M, Salotti J, McHugh K, Kim KP, Craft A, Lubin J, Ron E, Parker L. Socio-economic variation in the use of CT scans in young people in the North of England, 1990-2002. In: Journal of Epidemiology & Community Health: IEA World Congress of Epidemiology. 2011, Edinburgh: BMJ Group.
• McNally R, Gomez-Pozo B, Blakey K, James P, Pearce M, Craft A, Rushton S. Socioeconomic diversity and the incidence of childhood leukaemia in Northern England. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
• Pal D, Robson CN, Williamson SC, Nayernia K, Soleimanpour-Lichaei HR, Heer R. Stem-cell regulatory protein Piwil2 enriches for known stem-cell and cancer stem-cell markers in prostate cancer cells. In: British Journal of Surgery: Annual Meeting of the Society of Academic and Research Surgery. 2011, Dublin, Ireland: John Wiley & Sons Ltd.
• Canan S, Maegley K, Curtin N. Strategies employed for the development of PARP inhibitors. In: Virag, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2011, pp.463-89.
• Elliott PR, Liu H, Pastok MW, Grossmann GJ, Rigden DJ, Clague MJ, Urbé S, Barsukov IL. Structural variability of the ubiquitin specific protease DUSP-UBL double domains. FEBS Letters 2011, 585(21), 3385–3390.
• Basta NO, James PW, Gomez-Pozo B, Craft AW, McNally RJQ. Survival From Childhood and Young Adult Cancer in Northern England, 1968-2005. In: European Journal of Cancer: European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care. 2011, Stockholm, Sweden: Pergamon.
• Basta NO, James PW, Gomez-Pozo B, Craft AW, McNally RJ. Survival from childhood cancer in northern England, 1968-2005. British Journal of Cancer 2011, 105(9), 1402-1408.
• McNally R, Basta N, James P, Gomez-Pozo B, Craft A. Survival from childhood cancer in Northern England, 1968-2005. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
• Gomaa MS, Bridgens CE, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26). Journal of Medicinal Chemistry 2011, 54(19), 6803-6811.
• Plummer ER. Targeting DNA damage repair beyond PARP - further drugs or targets in development. In: Annals of Oncology: 9th International Symposium on Targeted Anticancer Therapies. 2011, Paris, France: Oxford University Press.
• Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GCM, Leung HY, Curtin NJ, Robson CN. Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer. PLoS One 2011, 6(5), e20311.
• Green S, Phoenix B, Mill AJ, Hill M, Charles MW, Thompson J, Jones B, Ngoga D, Detta A, James ND, Doran J, Graham N, Ghani Z, Wojnecki C, Halbert G, Elliott M, Ford S, Sheehan TMT, Vickerman J, Lockyer N, Croswell G, Boddy A, King A, Cruickshank GS. The Birmingham Boron Neutron Capture Therapy (BNCT) Project: Developments towards Selective Internal Particle Therapy [abstract]. Clinical Oncology 2011, 23(3), S23-S24.
• Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular Cancer Therapeutics 2011, 10(12), 2320-2329.
• Ferguson S, Gautrey HE, Strathdee G. The Dual Role of HLXB9 in Leukemia. Pediatric Blood & Cancer 2011, 56(3), 349-352.
• Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, Lübbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ET. Oncogene 2011, 30(27), 3062-3072.
• Oozeer NB, Corsar K, Glore RJ, Penney S, Patterson J, Paleri V. The impact of enteral feeding route on patient-reported long term swallowing outcome after chemoradiation for head and neck cancer. Oral Oncology 2011, 47(10), 980-983.
• Boyd KD, Ross FM, Drayson MT, Owen RG, Szubert AJ, Gregory WM, Wardell CP, Davies FE, Jackson GH, Child JA, Morgan GJ. The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Ruffin N, Ahmed SS, Osorio LM, Wang XN, Jackson GH, Collin MP, Ekre HP, Chiodi F, Dickinson AM. The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease. Transplantation 2011, 91(9), 946-951.
• Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Therapeutic Advances in Medical Oncology 2011, 3(6), 257-267.
• Delgado J, Canals C, Attal M, Thomson K, Campos A, Martino R, Littlewood T, Jackson G, Milpied N, Boogaerts M, Hunter A, Janssen JJWM, Montoto S, Sureda A. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia 2011, 25(3), 551-555.
• Sjoquist KM, Martyn J, Edmondson RJ, Friedlander ML. The Role of Hormonal therapy in Gynaecological Cancers – Current Status and Future Directions. International Journal of Gynecological Cancer 2011, 21(7), 1328-1333.
• Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. British Journal of Cancer 2011, 105(8), 1114-1122.
• Lochan R, Daly AK, Reeves HL, Charnley R. The role of tobacco derived carcinogens in pancreas cancer. ISRN Oncology 2011, 249235.
• Drew Y, Mulligan EA, Vong W, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. Journal of the National Cancer Institute 2011, 103(4), 334-346.
• Pridgeon SW, Heer R, Taylor GA, Newell DR, O'Toole K, Robinson M, Xu YZ, Karran P, Boddy AV. Thiothymidine combined with UVA as a potential novel therapy for bladder cancer. British Journal of Cancer 2011, 104(12), 1869-1876.
• Lindsey JC, Hill RM, Megahed H, Lusher ME, Schwalbe EC, Cole M, Hogg TL, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. TP53 Mutations in Favorable-Risk Wnt/Wingless-Subtype Medulloblastomas. Journal of Clinical Oncology 2011, 29(12), E344-E346.
• Arumugam T, Brandt W, Ramachandran V, Moore TT, Wang HM, May FE, Westley BR, Hwang RF, Logsdon CD. Trefoil Factor 1 Stimulates Both Pancreatic Cancer and Stellate Cells and Increases Metastasis. Pancreas 2011, 40(6), 815-822.
• Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EVA, Verrill MW, May FEB, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics 2011, 21(12), 808-819.
• Riedinger C, Noble ME, Wright DJ, Mulks F, Hardcastle I, Endicott JA, McDonnell JM. Understanding small-molecule binding to MDM2: Insights into structural effects of isoindolinone inhibitors from NMR spectroscopy. Chemical Biology and Drug Design 2011, 77(5), 301-308.
• Armstrong K, Ahmad I, Kalna G, Tan SS, Edwards J, Robson CN, Leung HY. Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. British Journal of Cancer 2011, 105(9), 1362-1369.
• Rodriguez SA, Clapham KM, Barrett L, Cano C, Desage ME, Griffin RJ, Hardcastle IR, Payne SL, Rennison T, Richardson C, Golding BT. Versatile Synthesis of Functionalised Dibenzothiophenes via Suzuki Coupling and Microwave-assisted Ring Closure. Organic & Biomolecular Chemistry 2011, 9(17), 6066-6074.
• Sinha A, Avery P, Turner S, Bailey S, Cheetham T. Vitamin D Status in Paediatric Patients With Cancer. Pediatric Blood & Cancer 2011, 57(4), 594-598.